在急性心力衰竭中使用静脉血管扩张剂的现行做法和前景:国际调查
Alessandro Galluzzo1, Maurizio Bertaina2, Julie K K Vishram-Nielsen3
1Department of Cardiology, Ospedale degli Infermi, Rivoli (Turin), Italy.
Journal of cardiovascular pharmacology
|August 20, 2025
概括
静脉输入血管扩张剂 (IVV) 治疗急性心力衰竭 (AHF) 很少使用,全球医生对其临床实践和看法存在很大差异. 需要进行进一步的试验,以确定在AHF中受益于IVV的特定患者群体.
科学领域:
- 心脏病学
- 临床实践
- 医学研究
背景情况:
- 静脉输入血管扩张剂 (IVV) 是治疗急性心力衰竭 (AHF) 的理论基础.
- 然而,临床试验证据不一致,导致指南建议较弱.
- 关于IVV在AHF治疗中的实践和临床医生的意见尚不清楚.
研究的目的:
- 调查国际临床实践和关于IVV在AHF使用的意见.
- 确定当前的趋势,首选的药物以及感知到的适应性/适应性.
- 为了突出IVV应用的异质性.
主要方法:
- 一个国际性的,基于网络的调查,包含29个项目,分发给管理AHF的心脏病专家.
- 这项调查探讨了说明,禁忌,药物选择,监测以及与其他疗法的相互作用.
- 分析了来自32个国家的170名医生的反应.
主要成果:
- 62%的受访者每月使用IVV治疗不到10名AHF患者.
- 甘油 (48%) 和酸 (29%) 是首选的药物.
- 在适应症 (例如,低输出HF,心脏性休克) 和适应症值 (低血压) 中存在显著差异.
结论:
- 目前在AHF中使用IVV是有限的,实践模式高度异质.
- 临床医生的意见在IVV管理的关键方面存在分歧,包括在ICU外使用和与口服疗法的相互作用.
- 预期试验对于确定受益于IVV的AHF患者子组至关重要.
相关概念视频
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Antihypertensive Drugs: Vasodilators
643
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
643


